Which chemo combo works best for breast cancer? major trial seeks answers
NCT ID NCT04193059
First seen Jan 05, 2026 · Last updated Jun 06, 2026 · Updated 25 times
Summary
This study compares two chemotherapy regimens for people with non-triple negative breast cancer after surgery. One group receives epirubicin plus cyclophosphamide followed by docetaxel (EC-T), while the other gets paclitaxel plus carboplatin (PCb). The goal is to see which combination better prevents the cancer from coming back. About 1,560 participants are enrolled, and the study is active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.